{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:14:15Z","timestamp":1718496855222},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1053\/j.seminhematol.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T15:29:41Z","timestamp":1711466981000},"page":"69-72","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial"],"prefix":"10.1053","volume":"61","author":[{"given":"Barbara","family":"Eichhorst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"ten Hacken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.seminhematol.2024.03.002_bib0001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.03.002_bib0002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.03.002_bib0003","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41408-021-00532-1","article-title":"Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.03.002_bib0004","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.03.002_bib0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"61","key":"10.1053\/j.seminhematol.2024.03.002_bib0041","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2024.01.009","article-title":"The molecular map of CLL and Richter\u2019s syndrome","volume":"2","author":"Sud","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2024.03.002_bib0008","doi-asserted-by":"crossref","first-page":"10933","DOI":"10.1038\/ncomms10933","article-title":"Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia","volume":"7","author":"Berndt","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.03.002_bib0009","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","article-title":"Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features","volume":"54","author":"Robbe","year":"2022","journal-title":"Nat Genet"},{"issue":"7574","key":"10.1053\/j.seminhematol.2024.03.002_bib0011","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.03.002_bib0012","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.03.002_bib0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.03.002_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/leu.2016.322","article-title":"Antigen receptor stereotypy in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"issue":"61","key":"10.1053\/j.seminhematol.2024.03.002_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.seminhematol.2023.12.005","article-title":"B cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients","volume":"2","author":"Agathangelidis","year":"2024","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.03.002_bib0016","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S2352-3026(14)00005-2","article-title":"Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study","volume":"1","author":"Baliakas","year":"2014","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.03.002_bib0017","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3324\/haematol.2019.231027","article-title":"Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL study group (GCLLSG)","volume":"105","author":"Jaramillo","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.03.002_bib0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"61","key":"10.1053\/j.seminhematol.2024.03.002_bib0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1053\/j.seminhematol.2024.02.002","article-title":"Prognostication in chronic lymphocytic leukemia","volume":"2","author":"Moia","year":"2024","journal-title":"Semin Hematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.03.002_bib0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.03.002_bib0021","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1080\/10428194.2018.1540782","article-title":"Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials","volume":"60","author":"Soumerai","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"61","key":"10.1053\/j.seminhematol.2024.03.002_bib0044","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.seminhematol.2024.04.002","article-title":"Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia","volume":"2","author":"Patton","year":"2024","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.03.002_bib0022","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.03.002_bib0023","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.03.002_bib0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"6682","key":"10.1053\/j.seminhematol.2024.03.002_bib0025","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science (New York, NY"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.03.002_bib0026","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"61","key":"10.1053\/j.seminhematol.2024.03.002_bib0043","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.seminhematol.2024.01.015","article-title":"Therapeutic targeting of apoptosis in chronic lymphocytic leukemia","volume":"2","author":"Ahn","year":"2024","journal-title":"Semin Hematol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.03.002_bib0027","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.03.002_bib0028","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.03.002_bib0029","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2174\/138161212801227023","article-title":"Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy","volume":"18","author":"Riches","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.03.002_bib0030","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","article-title":"A phase two study of high dose blinatumomab in Richter's syndrome","volume":"36","author":"Thompson","year":"2022","journal-title":"Leukemia"},{"issue":"7897","key":"10.1053\/j.seminhematol.2024.03.002_bib0031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"61","key":"10.1053\/j.seminhematol.2024.03.002_bib0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.seminhematol.2024.01.001","article-title":"Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies","volume":"2","author":"Borogovac","year":"2024","journal-title":"Semin Hematol"},{"issue":"10402","key":"10.1053\/j.seminhematol.2024.03.002_bib0032","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.03.002_bib0033","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2021014085","article-title":"Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination","volume":"139","author":"Herishanu","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.03.002_bib0034","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","article-title":"BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL","volume":"6","author":"Pleyer","year":"2022","journal-title":"Blood Adv"},{"issue":"61","key":"10.1053\/j.seminhematol.2024.03.002_bib0046","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.seminhematol.2024.01.003","article-title":"Vaccinations in patients with chronic lymphocytic leukemia","volume":"2","author":"Francis","year":"2024","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.03.002_bib0035","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ejh.14170","article-title":"Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia","volume":"112","author":"Mellinghoff","year":"2024","journal-title":"Eur J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:36:50Z","timestamp":1718411810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0037196324000556"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.03.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}